Biogen — Oct 30, 2024 release

3 Full Year 2024 Financial Guidance For the full year 2024, Biogen now expects a Non-GAAP diluted EPS guidance range as follows: Prior FY 2024 Guidance Updated FY 2024 Guidance Non-GAAP diluted EPS $15.75 to $16.25 Reflecting growth of ~9% at the mid-point* $16.10 to $16.60 Reflecting growth of ~11% at the mid-point* * Versus reported full year 2023 Biogen continues to expect total revenue to decline by a low-single digit percentage, with core pharmaceutical revenue, defined as product revenue plus Biogen's 50% share of net LEQEMBI product revenue and cost of sales, including royalties, to be relatively flat for 2024 compared to 2023 as further declines in multiple sclerosis product revenue are expected to be offset by increases in revenue from new product launches. Biogen continues to expect an improvement in the cost of sales as a percentage of total revenue for 2024 compared to 2023 driven by product mix and significantly lower idle capacity charges. For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with mid-single digit percentage point operating margin improvement. This is expected to be driven by improved cost of sales as a percentage of revenue, as well as lower operating expenses as a result of the Company's Fit for Growth and R&D prioritization initiatives. This financial guidance does not include any impact from potential acquisitions or business development transactions or pending and future litigation or any impact of potential tax or healthcare reform, as all are hard to predict. This guidance also assumes that foreign exchange rates as of October 25, 2024, will remain in effect for the remainder of the year, net of hedging activities. Other modeling considerations will be provided on the conference call and webcast. Biogen may incur charges, realize gain